NetScientific Subsidiary ProAxsis Licenses AstraZeneca Covid-19 Antibody Test
June 07 2021 - 1:57AM
Dow Jones News
By Anthony O. Goriainoff
NetScientific PLC said Monday that its subsidiary ProAxsis Ltd.
has entered into an exclusive licensing agreement with AstraZeneca
PLC for an antibody test for SARS-CoV-2, the virus which causes
Covid-19.
The London-listed life-sciences company said ProAxsis will
complete the validation and global commercialization of a
SARS-CoV-2 serology enzyme-linked immunosorbent assay developed at
AstraZeneca.
"This highly sensitive and specific blood test makes use of
simple and convenient fingerstick sample collection that will be
well suited to large scale deployment and has the potential to play
an important role in antibody analyses in large populations,"
AstraZeneca said.
The company said AstraZeneca will receive a royalty fee on
future global net sales of the assay.
"The assay could if fully validated potentially attract a
substantial market. It is envisaged that the validation and initial
commercialization can be achieved largely from ProAxsis' existing
resources," Chief Executive Ilian Iliev said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 07, 2021 02:50 ET (06:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024